BioNTech Operating Cycle from 2010 to 2026

BNTX Stock  USD 108.25  0.63  0.58%   
BioNTech Operating Cycle yearly trend continues to be fairly stable with very little volatility. Operating Cycle is likely to outpace its year average in 2026. During the period from 2010 to 2026, BioNTech Operating Cycle regression line of annual values had r-squared of  0.77 and arithmetic mean of  158.22. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
353.94
Current Value
371.63
Quarterly Volatility
146.6613142
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Net Interest Income of 513.2 M, Interest Income of 528.4 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 10.38, Dividend Yield of 0.011 or PTB Ratio of 1.27. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
  
Build AI portfolio with BioNTech Stock
Check out the analysis of BioNTech Correlation against competitors.
The evolution of Operating Cycle for BioNTech SE provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how BioNTech compares to historical norms and industry peers.

Latest BioNTech's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of BioNTech SE over the last few years. It is BioNTech's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

BioNTech Operating Cycle Regression Statistics

Arithmetic Mean158.22
Geometric Mean102.25
Coefficient Of Variation92.69
Mean Deviation125.37
Median85.46
Standard Deviation146.66
Sample Variance21,510
Range382
R-Value0.88
Mean Square Error5,197
R-Squared0.77
Slope25.54
Total Sum of Squares344,153

BioNTech Operating Cycle History

2026 371.63
2025 353.94
2024 393.26
2023 424.17
2022 186.08
2021 285.66
2020 158.47

About BioNTech Financial Statements

BioNTech investors use historical fundamental indicators, such as BioNTech's Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 353.94  371.63 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.